Lyell Immunopharma To Present Data From Its Current Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-Cell Lymphoma At European Hematology Association 2026 Congress

Loading news article.

Lyell Immunopharma To Present Data From Its Current Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-Cell Lymphoma At European Hematology Association 2026 Congress | WAPE

Lyell Immunopharma To Present Data From Its Current Phase 1/2 Clinical Study Of Rondecabtagene Autoleucel In Participants With Relapsed Or Refractory Large B-Cell Lymphoma At European Hematology Association 2026 Congress

Article summary

Related companies

Comments —